Hal Barron (GSK via YouTube)
May 31, 2022 07:05 AM EDT
Deals

GSK bets $3.3B on a buy­out, jump­ing in­to a block­buster show­down with Pfiz­er and Mer­ck

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

MD An­der­son tar­gets $250M for sec­ond can­cer biotech fund

No­var­tis won bid­ding war for kid­ney drug as Reg­u­lus' top three ex­ecs ex­pect to make over $100M com­bined

Strand Ther­a­peu­tics re­ports promis­ing start for mR­NA can­cer ther­a­py

In­flaRx cans Go­hibic de­vel­op­ment af­ter skin dis­ease tri­al stopped for fu­til­i­ty

FDA lead­er­ship preps for sum­mer bio­phar­ma lis­ten­ing tour across six cities

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times